

## **Point-by-point responses to the issues raised in the peer-review report**

(date 14.12.2020, Manuscript NO: 59071 - Notification on manuscript revision)

### **Comment on point 3 SCIENTIFIC QUALITY, Reviewer #1:**

The description of the enrolled samples was presented in the materials and methods section as advised by the Reviewer #1.

### **Comment on point 4 LANGUAGE QUALITY**

We use language editing service provided by the Filipodia Publishing. We subsequently provided the English Language Certificate issued by a professional English language editing company Filipodia Publishing.

### **Comment on point 5 EDITORIAL OFFICE'S COMMENTS**

#### **(1) Science editor:**

1 Scientific quality: (2) The description of the enrolled samples was presented in the materials and methods section as advised by the Reviewer #1.

3 Academic norms and rules: We subsequently provided:

- Signed Conflict-of-Interest Disclosure Form
- Signed Copyright License Agreement
- Clinical Trial Registration Statement and
- CONSORT 2010 statement

5 Issues raised: (1) We subsequently provided original figure using PowerPoint. (2) We subsequently wrote article highlight section.

#### **(3) Company editor-in-chief:**

We subsequently provided the English Language Certificate issued by a professional English language editing company Filipodia Publishing.